Lionel Piroth, P Tattevi, J-M Didelot, I Heard, Emmanuelle Ressiot, Pialoux, H Njatonirina, Tristan Ferry, J-D Combes, G M Clifford, Michaël Falguières, Jean-François Fléjou, Isabelle Heard, Jacques Reynes, Petrov Sanchez, G Maincent, Annie Lion, M Landon, Patey O, Jean-Damien Combes, Catherine Tamalet, L Marchand, Jean-Michel Didelot, Isabelle Etienney, T Ferry, Ana Canestri, F Le Breton, Cédric Arvieux, I Poizot-Martin, Laurent Siproudhis, L Piroth, I. Etienney, H Fischer, Gary M. Clifford, Olivier Patey, J-F Flejou, A-C Lesage, N Hoyau, S. Radenne, Sébastien Henno, Hélène Laude, J Del Grande, Lucie Marchand, Costes-Martineau, Isabelle Poizot-Martin, Herrada, Anthony, Centre International de Recherche contre le Cancer - International Agency for Research on Cancer (CIRC - IARC), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre National de Référence pour les Papillomavirus - Rétrovirologie moléculaire - Génétique,Papillomavirus et Cancer humain, Institut Pasteur [Paris] (IP), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'Immuno-hématologie clinique [Hôpital Sainte Marguerite - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Maladies infectieuses et tropicales [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Pontchaillou [Rennes], Département d'infectiologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques (CIC-EC), Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Intercommunal Villeneuve-Saint-Georges (CHIV), ANRS France Recherche Nord & sud Sida-hiv hépatites, Service d'Anatomie et cytologie pathologiques [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Dpt proctologie [CHU Croix St Simon], Groupe Hospitalier Diaconesses Croix Saint-Simon, This work was sponsored and funded by France Recherche Nord et Sud Sida-HIV et Hépatites (ANRS) [Convention No. 14730]., L. P. has received funding from Gilead, Janssen, MSD, and Viiv Healthcare for travel/accommodations/meeting expenses during the past 36 months not related to the submitted work. I. P. M. has received funding from Gilead, BMS, and Abbvie for board membership, from Gilead, MSD, and BMS as payment for lectures, including service on speakers bureaus, and from bms for travel/accommodations/meeting expenses during the past 36 months not related to the submitted work. All other authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., The ANRS EP57 APACHES study group would like to thank Marie Abrivard, Laurence Arowas, Sarah Azouaou, Véronique Chabanis, Sophie Circosta, Claude Crisol, Marie-Christine Demazoin, Anne Dumont, Susan Gamon, Philippine Gason, Damien Georges, Sandrine Gohier, Sophie Guillot, Alena Ivanova, Anne-Sophie Jouault, Hélène Laroche, Lydia Leger, Karine Lelandais, Emmanuelle Norguet, Sadia Medaouri, Stanislas Ogoudjobi, Enora Ouamara-Digue, Christelle Paul, Maja Ratajczak, Anne-Suzel Ritleng, Jennifer Rohan, Typhaine Thomas, Jérôme Vignat, Olivia Zaegel, and members of TRT-5. They are extremely grateful to all participants., Institut Pasteur [Paris], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service des maladies infectieuses et tropicales [CHU Tenon], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'anatomie et cytologie pathologiques [CHU Saint-Antoine], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Saint-Antoine [AP-HP]
A correction has been published:The Journal of Infectious Diseases, Volume 218, Issue 8, 15 October 2018, Page 1350, https://doi.org/10.1093/infdis/jiy315; International audience; Background:We assessed prevalence and risk factors for anal human papillomavirus (HPV) in human immunodeficiency virus (HIV)-positive men who have sex with men (MSM), who are at high-risk of HPV-related anal cancer.Methods:APACHES is a multicentric, prospective study of anal HPV infection and lesions in HIV-positive MSM aged ≥35 years. At baseline, participants underwent anal swabs for HPV and cytology, plus high-resolution anoscopy. High-risk HPV (HR-HPV) was tested by Cobas4800, with genotyping of HR-HPV positives by PapilloCheck.Results:Among 490 participants, prevalence of HPV16 and HR-HPV was 29% and 70%, respectively, and did not differ significantly by age, sexual behavior, or markers of HIV or immune deficiency. Smoking was the only, albeit weak (odds ratio, 1.8; 95% confidence interval, 1.2-2.7), predictor of HR-HPV. High-risk HPV and HPV16 prevalence increased strongly with anal diagnosis severity, both by worse cytological/histological (composite) diagnosis at APACHES baseline and worse historical diagnosis. HPV16 rose from 19% among participants who were negative for lesions to 63% among participants with high-grade lesions. In contrast, non-HPV16 HR-HPVs were less prevalent in high-grade (37%) than negative (64%) composite diagnosis, and their causal attribution was further challenged by multiple HPV infections.Conclusions:Human papillomavirus 16 is ubiquitously frequent among human immunodeficiency virus -positive men having sex with men, and more strongly associated with high-grade anal lesions than other high-risk types, confirming it as a target for anal cancer prevention.